Novartis, Artios Pharma Target Cancer in Up-to-$1.3B DDR Collaboration
Novartis, Artios Pharma Target Cancer in Up-to-$1.3B DDR Collaboration April 7, 2021 Share Artios Pharma CEO Niall Martin, PhD Novartis has agreed to identify and validate next-generation DNA Damage Response (DDR) targets for precision cancer treatments using Artios Pharma’s discovery platform, through a collaboration that could generate more than $1.3 billion for Artios. The companies plan to discover and validate targets that enhance Novartis’ Radioligand Therapies (RLTs) through a three-year research collaboration. Novartis will select up to three exclusive DDR targets, and receive wor...